All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld MedTech Perspectives » Obscurantism: Just another day in DC

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Obscurantism: Just another day in DC

Jan. 23, 2015
By Mark McCarty
No Comments

If only policy came together this seamlessly...maybe.
If only policy came together this seamlessly ... or is it just as well?

The federal government seems at times determined to make a blogger’s job easier, and recent events do little to dissuade one of that view.

Following are a couple of developments of interest to device makers, but we can’t be sure what’s real and what’s just more smoke and mirrors.

Is corporate tax reform kaput?

As we noted recently, Secretary of Commerce Penny Pritzker said in public that the administration wants revenue-neutral tax reform, but President Obama said little about taxes in the State of the Union address other than that he sees a need to boost taxes on the well-off in order to pay for free junior college and other things.

The President’s silence on the issue doesn’t mean corporate tax reform is DOA, but Pritzker was the first in this administration to say anything favorable toward revenue neutrality. Trust me when I say the GOP will not go for corporate tax reform that is revenue enhancing.

Nothing against Secretary Pritzker, but until I hear it from the horse’s mouth…

Taking the initiative or taking an initiative over?

One model of leadership is said to consist of finding a parade and jumping in front. At first glance, that seems to be the case with the President’s Personalized Medicine Initiative, which entirely ignores the fact that the House of Representatives has been working on just this for quite some time now in the guise of the 21st Century Cures initiative.

There’s another model of leadership that’s more or less prevalent in both the public and private sectors. It’s called, “take the credit for the work of others and pretend the idea was entirely yours.” I hear it’s great for morale and should go a long way toward easing tensions between 1600 Pennsylvania Ave. and Capitol Hill.

New questions of usability?

Just when you think you’ve heard it all, you read another FDA product development guidance. FDA’s draft guidance for “wellness devices,” states that the classification of such an offering may depend on whether the device presents “novel questions of usability.” That’s odd because the guidance seems to suggest at the outset that unless the intended use indicates a moderate degree of risk, these devices are presumed to be class I devices.

So how does a developer document that the wellness device does not present novel questions of usability? I don’t know. Human factors engineering? Studies of the article’s use in real-life settings?

I started my review of this draft guidance thinking it was a way to get some really basic mobile medical apps to market, but this question about novel questions suggests FDA is bound and determined to snare them all in its class II (or higher) regulatory tentacles. Shocking, no?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing